{"id":3163,"date":"2014-09-19T06:30:00","date_gmt":"2014-09-19T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-far-horizon-2020-finansiering\/"},"modified":"2014-09-19T06:30:00","modified_gmt":"2014-09-19T06:30:00","slug":"xvivo-far-horizon-2020-finansiering","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-horizon-2020-finansiering\/","title":{"rendered":"XVIVO f\u00e5r Horizon 2020 finansiering"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong>Den Europeiska kommissionen har valt XVIVO Perfusions projekt &#34;Biomark\u00f6rer f\u00f6r klinisk bed\u00f6mning av lungor avsedda f\u00f6r transplantation&#34; f\u00f6r finansiering genom forskning och innovationsprogrammet Horizon 2020.<\/strong><\/div>\n<\/p>\n<p><span><span>Sammanlagt 2.666 f\u00f6rslag l\u00e4mnades in till den f\u00f6rsta \u201dSME (Small Medium Enterprises) Instrument\u201d utlysningen inom den Europeiska kommissionens nyetablerade forskning och innovationsprogram Horizon 2020. 155 projekt fr\u00e5n 21 l\u00e4nder valdes ut f\u00f6r finansiering av en fas 1 f\u00f6rstudie. Varje projekt f\u00e5r 50.000 Euro f\u00f6r att utf\u00f6ra en genomf\u00f6rbarhetsstudie och att f\u00f6rbereda ett fas 2 program, vilket om det beviljas, kan komma att resultera i att ytterligare finansiering erh\u00e5lls. <\/span><\/span><\/p>\n<\/p>\n<p><span><span>&#34;Vi \u00e4r glada f\u00f6r att ha blivit utvalda i konkurrens med m\u00e5nga andra kvalificerade bolag. Fokus ligger nu p\u00e5 att n\u00e5 m\u00e5len f\u00f6r fas 1 och i f\u00f6rberedelserna inf\u00f6r en klinisk studie i projektfas 2, &#34;s\u00e4ger Petra Apell, regionchef p\u00e5 XVIVO Perfusion. <\/span><\/span><\/p>\n<\/p>\n<p><span><span>M\u00e5let med projektet \u00e4r att identifiera biomark\u00f6rer och medicintekniska produkter som kan ytterligare f\u00f6rb\u00e4ttra utv\u00e4rderingen av lungor vid Ex Vivo Lung Perfusion (EVLP). Lungtransplantation \u00e4r det enda behandlingsalternativet f\u00f6r vissa patienter som lider av allvarliga lungsjukdomar. Cirka 80 procent av alla donerade lungor anv\u00e4nds inte f\u00f6r transplantation idag. Den fr\u00e4msta orsaken \u00e4r os\u00e4kerhet om funktion och kvalitet av lungan. EVLP \u00e4r en teknik som anv\u00e4nds f\u00f6r att bed\u00f6ma kvaliteten p\u00e5 donerade lungor f\u00f6re transplantation. EVLP kan potentiellt leda till en \u00f6kning av utnyttjandegraden av donerade lungor fr\u00e5n dagens 20 procent till 40-60 procent. Validerade och objektiva parametrar f\u00f6r utv\u00e4rdering av lungor vid EVLP f\u00f6rv\u00e4ntas f\u00f6rb\u00e4ttra de kliniska resultaten vid lungtransplantationer efter EVLP. <\/span><\/span><\/p>\n<\/p>\n<p><span><span>&#34;Vi \u00e4r mycket glada \u00f6ver att den Europeiska kommissionen har beslutat att st\u00f6dja detta projekt ekonomiskt. Nya biomark\u00f6rer kan leda till fortsatt utveckling och expansion av organperfusionsmarknaden &#34;, s\u00e4ger Dr Magnus Nilsson, VD f\u00f6r XVIVO Perfusion.<\/span><\/span><\/p>\n<p><span><span>G\u00f6teborg 19 september 2014<br \/> XVIVO Perfusion AB (publ)<br \/> Magnus Nilsson <br \/> CEO<\/span><\/span><\/p>\n<div class=\"mfn-footer\">\n<p><span>F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n<p><span>Christoffer Rosenblad, CFO, tel: 031-788 21 59, e-post: <a href=\"mailto:christoffer.rosenblad@xvivperfusion.com\" rel=\"nofollow\">christoffer.rosenblad@xvivoperfusion.com<\/a><br \/>F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, <a href=\"http:\/\/www.xvivoperfusion.com\" rel=\"nofollow\">www.xvivoperfusion.com<\/a><\/span><\/p>\n<p><span>Informationen l\u00e4mnades f\u00f6r publicering den\u00a019 september 2014 kl. 8:30.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Den Europeiska kommissionen har valt XVIVO Perfusions projekt &#34;Biomark\u00f6rer f\u00f6r klinisk bed\u00f6mning av lungor avsedda f\u00f6r transplantation&#34; f\u00f6r finansiering genom&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-3163","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>XVIVO f\u00e5r Horizon 2020 finansiering - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-horizon-2020-finansiering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO f\u00e5r Horizon 2020 finansiering - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Den Europeiska kommissionen har valt XVIVO Perfusions projekt &#034;Biomark\u00f6rer f\u00f6r klinisk bed\u00f6mning av lungor avsedda f\u00f6r transplantation&#034; f\u00f6r finansiering genom...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-horizon-2020-finansiering\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-far-horizon-2020-finansiering\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-far-horizon-2020-finansiering\\\/\",\"name\":\"XVIVO f\u00e5r Horizon 2020 finansiering - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2014-09-19T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-far-horizon-2020-finansiering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-far-horizon-2020-finansiering\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-far-horizon-2020-finansiering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO f\u00e5r Horizon 2020 finansiering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO f\u00e5r Horizon 2020 finansiering - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-horizon-2020-finansiering\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO f\u00e5r Horizon 2020 finansiering - XVIVO","og_description":"Den Europeiska kommissionen har valt XVIVO Perfusions projekt &#34;Biomark\u00f6rer f\u00f6r klinisk bed\u00f6mning av lungor avsedda f\u00f6r transplantation&#34; f\u00f6r finansiering genom...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-horizon-2020-finansiering\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-horizon-2020-finansiering\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-horizon-2020-finansiering\/","name":"XVIVO f\u00e5r Horizon 2020 finansiering - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2014-09-19T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-horizon-2020-finansiering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-horizon-2020-finansiering\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-horizon-2020-finansiering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO f\u00e5r Horizon 2020 finansiering"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}